Download PDF
Synlett 2002(1): 0093-0096
DOI: 10.1055/s-2002-19358
LETTER
© Georg Thieme Verlag Stuttgart · New York

Solid-Phase Synthesis of 6-Sulfonylamino Morphinan Libraries

Hiroshi Ohnoa, Kuniaki Kawamuraa, Atsushi Otakea, Hiroshi Nagase*a, Hiroshi Tanakab, Takashi Takahashi*b
Department of Medicinal Chemistry, Pharmaceutical Research Laboratory, Toray Industries, Inc.,, 1111 Tebiro, Kamakura, Kanagawa 248-8555, Japan
Fax: +81(467)324791; e-Mail: hiroshi_nagase@nts.toray.co.jp;
Department of Applied Chemistry, Tokyo Institute of Technology, 2-12-1 Ookayama, Meguro, Tokyo 152-8552, Japan
Fax: +81(3)57342884; e-Mail: ttakashi@o.cc.titech.ac.jp;
Further Information

Publication History

Received 19 October 2001
Publication Date:
01 February 2007 (online)

    Permissions and Reprints All articles of this category

Abstract

A solid-phase synthesis of 6-sulfonylamino morphinan has been developed. The morphinan derivatives were designed as selective opioid ligands. The sulfonamide moiety was introduced by reductive amination of a ketone on solid phase, followed by sulfonylation of the resulting amine. Using this methodology, the synthesis of three combinatorial libraries was accomplished to prepare 339 morphinan derivatives with over 70% purity.

Key words

opioid - morphinan - solid-phase synthesis - ketones - sulfonamides

    References

  • 1a Sencei P. Solid-Phase Synthesis and Combinatorial Technology   Willy-Interscience; New York: 2000. 
    Google Scholar
  • 1b Dorwald FZ. Organic Synthesis on Solid Phase   Willy-VCH; New York: 2000. 
    Google Scholar
  • 2 Matsuda A. Doi T. Tanaka H. Takahashi T. Synlett  2001,  1101 
    Article in Thieme ConnectGoogle Scholar
  • 3 Review of opioid compounds: Misicka A. Acta. Pol. Pharm.  1995,  52:  349 
    Google Scholar
  • 4 Nagase H. Hayakawa J. Kawamura K. Kawai K. Takezawa Y. Matsuura H. Tajima C. Endo T. . Chem. Pharm. Bull.  1998,  46:  366 
    Google Scholar
  • Message-address concept is that an opiod ligand can be divided into a message structure part and an address structural part:
  • 5a Portoghese PS. Lipkowski AW. Takemori AE. J. Med. Chem.  1987,  30:  238 
    CrossrefGoogle Scholar
  • 5b Portoghese PS. Sultana M. Nagase H. Takemori AE. J. Med. Chem.  1988,  31:  281 
    CrossrefGoogle Scholar
  • 6 Nogrady T. Medicinal Chemistry   In Oxford University Press; New York: 1985.  p.68 
    Google Scholar
  • 8a Boojamra CG. Burow KM. Thompson LA. Ellman JA. J. Org. Chem.  1997,  62:  1240 
    CrossrefGoogle Scholar
  • 8b Kim SW. Ahn SY. Koh JS. Lee JH. Ro S. Cho HY. Tetrahedron Lett.  1997,  38:  4603 
    CrossrefGoogle Scholar
  • 8c Swayze EE. Tetrahedron Lett.  1997,  38:  8465 
    CrossrefGoogle Scholar
  • 8d Swayze EE. Tetrahedron Lett.  1997,  38:  8643 
    CrossrefGoogle Scholar
  • 8e Devraj R. Cushman M. J. Org. Chem.  1996,  61:  9368 
    CrossrefGoogle Scholar
  • 8f Bray AM. Chiefari DS. Valerio RM. Maeji NJ. Tetrahedron Lett.  1995,  36:  5081 
    CrossrefGoogle Scholar
  • 9 Synthesis of 6α- and 6β-methylamino morphinans: Mohamed MS. Larson DL. Takemori AE. Portoghese PS. J. Med. Chem.  1986,  29:  1551 
    CrossrefGoogle Scholar
  • 10 The ratio 9/11 was determined by MS peak height: Andrew MB. Debra SC. Robert MV. Maeji JN. Tetrahedron Lett.  1995,  5081 
    Google Scholar
  • 11 Fivush AM. Willson TM. Tetrahedron Lett.  1997,  38:  7151 
    CrossrefGoogle Scholar
  • 12a Nicolaou KC. Xiao XY. Parandoosh Z. Senyei A. Nova MP. Angew. Chem. Int. Ed. Engl.  1995,  34:  2289 
    Google Scholar
  • 12b

    IRORI, P.O. Box 502778, San Diego, CA 92150-2778, www.irori.com.
7

Column: HYPERSIL ODS 5 µm, 4.6 × 150 mm; mobile phase: 20 mM AcONH4:MeOH = 70:30 (0 min)-10:90 (6-12 min); UV: 254 nm.

13

General procedure for the solid phase synthesis of 6-sulfonamido-morphinans 2: To a mixture of Wang resin (NOVA; 0.72 mmol/g, 4.00 g, 2.88 mmol), naltrexone (5) (4.37 g, 12.8 mmol) and PPh3 (1.78 g, 6.8 mmol) in THF was slowly added a 40% toluene solution of DEAD (3.10 mL, 6.8 mmol). The resulting suspension was shaken at room temperature for 19 h. The solvents were then removed by filtration and the resulting beads were washed with THF, DMF, MeOH, THF, and CH2Cl2, and dried in vacuo to give resin-supported naltrexone 4 (5.26 g). The beads (31 mg) were packed in Microkans, and 14 Microkans in DMF-MeOH-HOAc (100:10:1) (14 mL) were treated with methylamine hydrochloride (143 mg, 2.1 mmol) and NaBH3CN (267 mg, 4.06 mmol). After being shaken for 28 h, the mixture was filtered, washed with DMF, MeOH, THF, and CH2Cl2, and dried in vacuo to give resin 8a. To one of the resulting Microkans in CH2Cl2 (1 mL), DIEA (188 µL, 1.08 mmol) and p-toluenesulfonyl chloride (107 mg, 0.54 mmol) were added. The mixture was shaken for 2 h, filtered, washed with THF, DMF, MeOH, THF, and CH2Cl2, and dried in vacuo. The resulting Microkan was treated with 10% TFA/CH2Cl2 (2 mL) for 30 min, filtered, and then washed with CH2Cl2. The combined filtrates were evaporated, and dried in vacuo to give 14.6 mg of morphinan compound 2aA TFA salt with 96% purity determined by reversed-phase HPLC. MS m/z 511 ((M + H)+). a-2c 1H NMR (270 MHz, CDCl3) δ 0.09-0.15 (1H, m), 0.50-0.57 (2H, m), 0.80-0.90 (2H, m), 1.04-1.14 (1 H, m), 1.38 (1 H, dd, J = 8.6, 14.9 Hz), 1.55-1.69 (2 H, m), 2.18-2.32 (3 H, m), 2.35-2.44 (1 H, m), 2.41 (3 H, s), 2.50-2.59 (1 H, m), 2.62-2.67 (1 H, m), 2.88 (3 H, s), 3.01 (1 H, d, J = 18.8 Hz), 3.08 (1 H, d, J = 6.6 Hz), 4.49 (1 H, ddd, J = 3.8, 3.8, 13.1 Hz), 4.79-4.81 (1 H, m), 6.51 (1 H, d, J = 7.9 Hz), 6.70 (1 H, d, J = 7.9 Hz), 7.29 (2 H, d, J = 7.9 Hz), 7.74 (2 H, d, J = 8.6 Hz); 13C NMR (67.8 MHz, CDCl3) δ 3.8, 4.2, 9.4, 17.5, 21.6, 22.9, 29.8, 30.2, 31.7, 33.7, 43.1, 48.2, 53.1, 59.7, 62.0, 69.5, 94.4, 117.2, 119.2, 126.0, 127.1, 129.8, 130.8, 136.5, 137.4, 143.2, 145.4; IR(neat) 3355, 2928, 1616, 1463, 1337, 1152, 940, 859, 757, 666 cm-1. HRMS (ESI) 511 (M + H+), calcd 511.2267, found 511.2280. b-2c 1H NMR (270 MHz, CDCl3) δ 0.09-0.14 (2 H, m), 0.49-0.55 (2 H, m), 0.77-0.90 (2 H, m), 1.13-1.23 (1 H, m), 1.33-1.60 (3 H, m), 1.93-2.26 (3 H, m), 2.36 (2 H, d, J = 6.6 Hz), 2.41 (3 H, s), 2.53-2.66 (2 H, m), 2.85 (3 H, s), 3.00 (1 H, d, J = 10.6 Hz), 3.05 (1 H, s), 3.75 (1 H, ddd, J = 4.6, 8.3, 12.9 Hz), 4.50 (1 H, d, J = 7.9 Hz), 6.59 (1 H, d, J = 9.3 Hz), 6.75 (1 H, d, J = 8.3 Hz), 7.27 (2 H, d, J = 8.3 Hz), 7.67 (2 H, d, J = 8.6 Hz); 13C NMR (67.8 MHz, CDCl3) δ 3.9, 3.9, 9.5, 21.6, 22.0, 22.7, 29.6, 30.5, 30.8, 44.0, 48.1, 58.8, 59.2, 62.4, 70.1, 89.4, 117.7, 119.4, 124.5, 127.3, 129.6, 131.2, 137.3, 140.3, 142,2, 143.2; IR(neat) 3350, 2831, 1622, 1394, 1337, 1157, 918, 875, 758, 657 cm-1. HRMS (ESI) 511 (M + H+), calcd 511.2267, found 511.2266.